PDS Biotechnology Corp

EU6

Company Profile

  • Business description

    PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

  • Contact

    303A College Road
    East PrincetonNJ08540
    USA

    T: +1 800 208-3343

    E: [email protected]

    https://www.pdsbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    21

Stocks News & Analysis

stocks

Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity

Ongoing rate hikes have investors spooked.
stocks

ASX dividend champions: Stocks, ETFs and LICs

Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.
stocks

SpaceX’s IPO filing: Big spending, big losses

The first public financials from Elon Musk’s company highlight Starlink’s revenue power and increased spending on AI.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,856.306.000.07%
CAC 408,117.42135.661.70%
DAX 4024,737.24336.591.38%
Dow JONES (US)50,009.35645.471.31%
FTSE 10010,432.34101.790.99%
HKSE25,620.5830.54-0.12%
NASDAQ26,270.36399.651.54%
Nikkei 22561,945.342,140.933.58%
NZX 50 Index12,803.4142.380.33%
S&P 5007,432.9779.361.08%
S&P/ASX 2008,635.507.500.09%
SSE Composite Index4,174.7912.610.30%

Market Movers